Adoptive T-cell therapy: Optimizing chemokine receptor- mediated homing of T cells in cancer immunotherapy

Cancer Immunology: Bench to Bedside Immunotherapy of Cancers

Volumn , Issue , 2015, Pages 263-282

  Siddiqui, Imran ^a   Mantovani, Alberto ^a,b   Allavena, Paola ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943651687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-44946-2_14     Document Type: Chapter

References (181)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012; 62: 220-41.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62: 10-29.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med. 2004; 10: 909-15.
4. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology. 2012; 1: 306-15.
5. Blattman JN, Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science. 2004; 305: 200-5.
6. Rosenberg SAS. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol. 2011; 8: 577-85.
7. Smith FOF, Downey SGS, Klapper JAJ, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008; 14: 5610-8.
8. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008; 26: 5748-54.
9. Hodi FS, O‘Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
10. Robert C, Thomas L, Bondarenko I, O‘Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-26.
11. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313: 1485-92.
12. Galluzzi LL, Senovilla LL, Zitvogel LL, Kroemer GG. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012; 11: 215-33.
13. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring ofantiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011; 30: 83-95.
14. Finn OJO. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003; 3: 630-41.
15. Sasada T, Noguchi M, Yamada A, Itoh K. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother. 2012; 8(9): 1309-13.
16. Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol. 2012; 91: 53-8.
17. KantoffPW, Higano CS, Shore ND, Berger R, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-22.
18. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 3089-94.
19. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen- dependent prostate cancer. Clin Cancer Res. 2011; 17: 4558-67.
20. KantoffPW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 1099-105.
21. Abastado J-P. The next challenge in cancer immunotherapy: Controlling T-cell traffic to the tumor. Cancer Res. 2012; 72: 2159-61.
22. Rosenberg SAS, Yang JCJ, Sherry RMR, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-7.
23. Gattinoni LL, Powell DJD, Rosenberg SAS, Restifo NPN. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006; 6: 383-93.
24. Shlomchik WDW. Graft-versus-host disease. Nat Rev Immunol. 2007; 7: 340-52.
25. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007; 7: 790-802.
26. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957; 3: 241-52.
27. Bortin MM, Rimm AA, Saltzstein EC. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science. 1973; 179: 811-3.
28. Bortin MM, Truitt RL, Rimm AA, Bach FH. Graftversus- leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature. 1979; 281: 490-1.
29. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia:experimental and clinical results. Cancer Res. 1965; 25: 1525-31.
30. Schwarzenberg LL, Mathé GG, Schneider MM, Amiel JLJ, Cattan AA, Schlumberger JRJ. Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet. 1966; 2: 365-8.
31. Horowitz MMM, Gale RPR, Sondel PMP, Goldman JMJ, Kersey JJ, Kolb HJH, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood. 1990; 75: 555-62.
32. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus- host disease. N Engl J Med. 1981; 304: 1529-33.
33. Collins RHR, Rogers ZRZ, Bennett MM, Kumar VV, Nikein AA, Fay JWJ. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus- leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 1992; 10: 391-5.
34. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988; 108: 806-14.
35. Slavin SS, Naparstek EE, Nagler AA, Ackerstein AA, Kapelushnik JJ, Or RR. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995; 23: 1553-62.
36. Kolb HJH, Mittermüller JJ, Clemm CC, Holler EE, Ledderose GG, Brehm GG. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76: 2462-5.
37. Alexandros Spyridonidis ML. A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells. Am J Blood Res. 2012; 2: 98-104.
38. Finn OJ. Cancer immunology. N Engl J Med. 2008; 358: 2704-15.
39. Restifo NPN, Dudley MEM, Rosenberg SAS. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12: 269-81.
40. Hung KK, Hayashi RR, Lafond-Walker AA, Lowenstein CC, Pardoll DD, Levitsky HH. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998; 188: 2357-68.
41. Oble DA, Loewe R, Yu P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009; 9: 3.
42. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-4.
43. Laghi LL, Bianchi PP, Miranda EE, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis:a longitudinal study. Lancet Oncol. 2009; 10: 877-84.
44. Schaer DA, Lesokhin AM, Wolchok JD. Hiding the road signs that lead to tumor immunity. J Exp Med. 2011; 208: 1937-40.
45. Cohen PJP, Lotze MTM, Roberts JRJ, Rosenberg SAS, Jaffe ESE. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol. 1987; 129: 208-16.
46. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 1989; 49: 7086-92.
47. Cole DJD, Taubenberger JKJ, Pockaj BAB, Yannelli JRJ, Carter CC, Carrasquillo JJ, Leitman SS, Steinberg SMS, Rosenberg SAS, Yang YCY. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1994; 38: 299-303.
48. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indiumlabeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994; 73: 1731-7.
49. Ogawa MM, Tsutsui TT, Zou JPJ, Mu JJ, Wijesuriya RR, Yu WGW, et al. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res. 1997; 57: 2216-22.
50. Germain RNR. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 1994; 76: 287-99.
51. Davis MMM, Boniface JJJ, Reich ZZ, Lyons DD, Hampl JJ, Arden BB, et al. Ligand recognition by alpha beta T cell receptors. Immunology. 1997; 16: 523-44.
52. Butcher ECE, Picker LJL. Lymphocyte homing and homeostasis. Science. 1996; 272: 60-6.
53. Locati MM, Murphy MPM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Medicine (Abingdon). 1998; 50: 425-40.
54. Campbell JJJ, Butcher ECE. Chemokines in tissuespecific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000; 12: 336-41.
55. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Immunology. 1999; 18: 593-620.
56. Fefer AA. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 1969; 29: 2177-83.
57. Greenberg PDP, Cheever MAM, Fefer AA. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981; 154: 952-63.
58. Rosenberg SAS, Terry WDW. Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1976; 25: 323-88.
59. June CH. Adoptive T, cell therapy for cancer in the clinic. J Clin Invest. 2007; 117: 1466-76.
60. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007; 117: 1204-12.
61. Yang JCJ, Rosenberg SAS. Current approaches to the adoptive immunotherapy of cancer. Adv Exp Med Biol. 1987; 233: 459-67.
62. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2009; 33: 1-7.
63. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010; 16: 2646-55.
64. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013; 8(4):e60031.
65. Dudley MEM, Wunderlich JRJ, Yang JCJ, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23: 2346-57.
66. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-4.
67. GoffSL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma:analysis of tumors resected for TIL. J Immunother. 2010; 33: 840-7.
68. Hughes MSM, Yu YYLY, Dudley MEM, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005; 16: 457-72.
69. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005; 174: 4415-23.
70. Roszkowski JJJ, Lyons GEG, Kast WMW, Yee CC, Van Besien KK, Nishimura MIM. Simultaneous generation of CD8+ and CD4+ melanoma-reactiveT cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005; 65: 1570-6.
71. Engels BB, Noessner EE, Frankenberger BB, Blankenstein TT, Schendel DJD, Uckert WW. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther. 2005; 16: 799-810.
72. Cohen CJC, Zheng ZZ, Bray RR, Zhao YY, Sherman LAL, Rosenberg SAS, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol. 2005; 175: 5799-808.
73. Morgan RAR, Dudley MEM, Wunderlich JRJ, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126-9.
74. Johnson LAL, Heemskerk BB, Powell DJD, Cohen CJC, Morgan RAR, Dudley MEM, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006; 177: 6548-59.
75. Morgan RAR, Dudley MEM, Yu YYLY, Zheng ZZ, Robbins PFP, Theoret MRM, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003; 171: 3287-95.
76. Kalos M, Levine BL, Porter DL. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science. 2011; 3(95): 95Ra73.
77. Yvon E, Del Vecchio M, Savoldo B, Hoyos V. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009; 14(18): 5852-60.
78. Wu RR, Forget M-AM, Chacon JJ, Bernatchez CC, Haymaker CC, Chen JQJ, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012; 18: 160-75.
79. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009; 21(2): 233-40.
80. Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010; 16: 5458-68.
81. Fisher BB, Packard BSB, Read EJE, Carrasquillo JAJ, Carter CSC, Topalian SLS, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989; 7: 250-61.
82. Kedl RMR, Mescher MFM. Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor. J Immunol. 1997; 159: 650-63.
83. Zlotnik AA, Yoshie OO. Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12: 121-7.
84. Vicari APA, Caux CC. Chemokines in cancer. Cytokine Growth Factor Rev. 2002; 13: 143-54.
85. Balkwill FF. Cancer and the chemokine network. Nat Rev Cancer. 2004; 4: 540-50.
86. Bellone M, Calcinotto A, Corti A. Won‘t you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology. 2010; 1: 986-8.
87. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev. 2012; 32: 1078-91.
88. Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol. 2008; 29: 235-41.
89. Dirkx AEM, oude Egbrink MGA, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyteendothelium interactions and infiltration in tumors. FASEB J. 2006; 20: 621-30.
90. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF- secreting cancer immunotherapy. Clin Cancer Res. 2006; 12: 6808-16.
91. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010; 70: 6171-80.
92. Manning EA, Ullman JGM, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007; 13: 3951-9.
93. Murphy PMP. The molecular biology of leukocyte chemoattractant receptors. Immunology. 1993; 12: 593-633.
94. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol. 1999; 19: 1-47.
95. Sallusto F, Kremmer E, Palermo B, Hoy A, Ponath P, Qin S, et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol. 1999; 29: 2037-45.
96. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010; 21: 27-39.
97. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Immunology. 1999; 18: 217-42.
98. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2010; 317(5): 664-73.
99. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulateinflammatory cytokines and chemokines. Trends Immunol. 2001; 22: 328-36.
100. Locati M, de LTorre YM, Galliera E, Bonecchi R, Bodduluri H, Vago G, et al. Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Trends Immunol. 2005; 16: 679-86.
101. Viola A, Molon B, Contento RL. Chemokines:coded messages for T-cell missions. Front Biosci (Elite Ed). 2007; 13: 6341-53.
102. Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine. 2008; 44: 1-8.
103. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008; 454: 436-44.
104. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Publ Group. 2010; 11: 889-96.
105. Bonecchi R, Locati M, Mantovani A. Chemokines and cancer: a fatal attraction. Cancer Cell. 2011; 19: 434-5.
106. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002; 2: 664-74.
107. Schadendorf DD, Möller AA, Algermissen BB, Worm MM, Sticherling MM, Czarnetzki BMB. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 1993; 151: 2667-75.
108. Mrowietz UU, Schwenk UU, Maune SS, Bartels JJ, Küpper MM, Fichtner II, et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer. 1999; 79: 1025-31.
109. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011; 470: 548-53.
110. Lechner MG, Russell SM, Bass RS, Epstein AL. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011; 3(11): 1317-40.
111. Förster RR, Schubel AA, Breitfeld DD, Kremmer EE, Renner-Müller II, Wolf EE, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99: 23-33.
112. Homey BB, Müller AA, Zlotnik AA. Chemokines:agents for the immunotherapy of cancer? Nat Rev Immunol. 2002; 2: 175-84.
113. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000; 164: 4558-63.
114. Vicari APA, Ait-Yahia SS, Chemin KK, Mueller AA, Zlotnik AA, Caux CC. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000; 165: 1992-2000.
115. Braun SES, Chen KK, Foster RGR, Kim CHC, Hromas RR, Kaplan MHM, et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol. 2000; 164: 4025-31.
116. Kirk CJC, Hartigan-O‘Connor DD, Nickoloff BJB, Chamberlain JSJ, Giedlin MM, Aukerman LL, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001; 61: 2062-70.
117. Kirk CJC, Hartigan-O‘Connor DD, Mule JJJ. The dynamics of the T-cell antitumor response:chemokine- secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001; 61: 8794-802.
118. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010; 328: 749-52.
119. Dubinett SMS, Lee JMJ, Sharma SS, Mulé JJJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J. 2010; 16: 325-35.
120. Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010; 10: 725-33.
121. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002; 13: 455-81.
122. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2002; 267: 271-85.
123. Uekusa YY, Yu W-GW, Mukai TT, et al. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 2002; 62: 3751-8.
124. Parker JNJ, Meleth SS, Hughes KBK, Gillespie GYG, Whitley RJR, Markert JMJ. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005; 12: 359-68.
125. Nagai M, Masuzawa T. Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Int Immunopharmacol. 2001; 1: 657-64.
126. Hirose KK, Hakozaki MM, Nyunoya YY, Kobayashi YY, Matsushita KK, Takenouchi TT, et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer. 1995; 72: 708-14.
127. Cao Q, Jin Y, Jin M, He S, Gu Q, He S, Qiu Y, Ge H, Yoneyama H, Zhang Y. Therapeutic effect of MIP-1alpha- recruited dendritic cells on preestablished solid and metastatic tumors. Cancer Lett. 2010; 295: 17-26.
128. Aravindaram K, Yu H-H, Lan C-W, Wang P-H, Chen Y-H, Chen H-M, et al. Transgenic expression ofhuman gp100 and RANTES at specific time points for suppression of melanoma. Gene Ther. 2009; 16: 1329-39.
129. Inoue HH, Iga MM, Xin MM, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother. 2008; 57: 1399-411.
130. Song S, Liu C, Wang J, Zhang Y, You H, Wang Y, Liu F, Sun S. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine. 2009; 27: 1111-8.
131. Pan JJ, Burdick MDM, Belperio JAJ, Xue YYY, Gerard CC, Sharma SS, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol. 2006; 176: 1456-64.
132. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol. 2008; 217: 21-31.
133. Musha HH, Ohtani HH, Mizoi TT, Kinouchi MM, Nakayama TT, Shiiba KK, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer. 2005; 116: 949-56.
134. Zeng YY, Huebener NN, Fest SS, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res. 2007; 67: 2331-8.
135. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 2004; 26: 41-7.
136. Ludwig AA, Schulte AA, Schnack CC, Hundhausen CC, Reiss KK, Brodway NN, et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem. 2005; 93: 1293-303.
137. Wente MNM, Gaida MMM, Mayer CC, Michalski CWC, Haag NN, Giese TT, et al. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol. 2008; 33: 297-308.
138. Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res. 2008; 68: 4701-8.
139. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008; 181: 3099-107.
140. Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermüller N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer. 2009; 45: 478-89.
141. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007; 67: 4725-31.
142. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One. 2008; 4:e6695.
143. Rutledge BJB, Rayburn HH, Rosenberg RR, North RJR, Gladue RPR, Corless CLC, Rollins BJB. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol. 1995; 155: 4838-43.
144. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res. 1997; 57: 4849-54.
145. Kurt RAR, Baher AA, Wisner KPK, Tackitt SS, Urba WJW. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol. 2001; 207: 81-8.
146. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11: 130.
147. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010; 102(8): 522-8.
148. Zou WW, Machelon VV, Coulomb-L‘Hermin AA, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001; 7: 1339-46.
149. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010; 29: 709-22.
150. Chen D, Bromberg JS. T regulatory cells and migration. Am J Transplant. 2006; 6: 1518-23.
151. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8: 618-31.
152. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010; 70: 109-18.
153. Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol. 2011; 104: 83-92.
154. Ueha S, Yoneyama H, Hontsu S, Kurachi M, Kitabatake M, Abe J, et al. CCR7 mediates the migration of Foxp3+ regulatory T cells to the paracortical areas of peripheral lymph nodes through high endothelial venules. J Leukoc Biol. 2007; 82: 1230-8.
155. Mackay CRC, Marston WLW, Dudler LL. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med. 1990; 171: 801-17.
156. D‘Ambrosio DD, Iellem AA, Bonecchi RR, Mazzeo DD, Sozzani SS, Mantovani AA, Sinigaglia FF. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998; 161: 5111-5.
157. Peled AA, Grabovsky VV, Habler LL, Sandbank JJ, Arenzana-Seisdedos FF, Petit II, Ben-Hur HH, Lapidot TT, Alon RR. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest. 1999; 104: 1199-211.
158. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002; 119: 492-5.
159. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002; 13: 1971-80.
160. Zhang TT, Somasundaram RR, Berencsi KK, Caputo LL, Gimotty PP, Rani PP, Guerry DD, Swoboda RR, Herlyn DD. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. 2006; 36: 457-67.
161. Kunz MM, Toksoy AA, Goebeler MM, Engelhardt EE, Bröcker EE, Gillitzer RR. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol. 1999; 189: 552-8.
162. Zhang TT, Somasundaram RR, Berencsi KK, Caputo L, Rani P, Guerry D, et al. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4- dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol. 2005; 174: 5856-63.
163. Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol. 2006; 176: 2902-14.
164. Campbell JJJ, Bowman EPE, Murphy KK, Youngman KRK, Siani MAM, Thompson DAD, Wu LL, Zlotnik AA, Butcher ECE. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol. 1998; 141: 1053-9.
165. Loetscher MM, Gerber BB, Loetscher PP, Jones SAS, Piali LL, Clark-Lewis II, Baggiolini MM, Moser BB. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996; 184: 963-9.
166. Farber JMJ. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997; 61: 246-57.
167. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol. 1999; 67: 53-62.
168. Chuntharapai AA, Lee JJ, Hébert CAC, Kim KJK. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994; 153: 5682-8.
169. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, SlingluffC, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009; 69: 3077-85.
170. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010; 33(8): 780-8.
171. Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother. 2012; 61(10): 1833-47.
172. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007; 179: 3332-41.
173. Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, Daniel J, Powell J, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011; 17: 4719-30.
174. Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One. 2013; 8:e56820.
175. Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, et al. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer. 2010; 18: 1-10.
176. Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008; 68: 9060-9.
177. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A, Allavena P. Expression of chemokines and chemokine receptors in human colon cancer. Meth Enzymol. 2009; 460: 105-21.
178. Sans M, Danese S, de La Motte C, de Souza HSP, Rivera Reyes BM, West GA, Phillips M, Katz JA, Fiocchi C. Enhanced recruitment of CX3CR1+ T cells by muco-sal endothelial cell-derived Fractalkine in inflammatory bowel disease. Gastroenterology. 2007; 132: 139-53.
179. Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol. 2012; 106(4): 386-92.
180. Choi D, Kim T-G, Sung YC. The past, present, and future of adoptive T cell therapy. Immune Netw. 2012; 12: 139-47.
181. Hoyos V, Savoldo B, Dotti G. Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012; 97: 1622-31.